• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

14 Pharma Companies Recognized on Dow Jones Sustainability Index


16 September, 2015.

Fourteen pharma companies make this year's Dow Jones Sustainability Indices (DJSI) review, assembled by S&P Dow Jones Indices and RobecoSAM, an investment specialist focused on sustainability investing.   Launched in 1999, the DJSI World tracks the leading sustainability-driven companies worldwide, based on RobecoSAM's analysis of financially material environmental, social, and governance (ESG) factors. RobecoSAM invited the world's largest 3,400 companies from developed and emerging markets to take part in its annual Corporate Sustainability Assessment (CSA).    The 14 pharma companies retaining or earning their spot in the Review this year are:

  • Abbvie (US)

  • Actelion (Switzerland)

  • Agilent Technologies

  • Amegen (US)

  • AstraZeneca (UK)

  • Baxalta (US)

  • Bayer (Germany)

  • Biogen (US)

  • GSK (UK)

  • Indivior (UK)

  • Novartis (Switzerland)

  • Novo Nordisk (Denmark)

  • Roche (Switzerland)

  • Sanofi (France)

Guido Giese, Head of Indices, RobecoSAM commented: "Over the years the DJSI index family has not only come to be the gold standard for corporate sustainability but has also become a competitive platform where companies receive recognition for their sustainability practices." David Blitzer, MD and Chairman of the Index Committee at S&P Dow Jones Indices, added that more and more investors are looking at at companies' environmental policies and track records when making their investment decisions.    For further information on this year's DJSI Review, visit


Related Videos